Serina Therapeutics Appoints Karen J. Wilson to Board of Directors

Serina Therapeutics Inc., NanoScales, and Fragments of Preclinical Data—SER, a clinical-stage biotech company deploying the POZ PlatformTM drug delivery technology, has appointed Karen J. Wilson to its Board of Directors. As of now, Ms. Wilson holds over three decades of experience in the life sciences industry with in-depth knowledge of finance and strategic planning. She has held senior positions at Jazz Pharmaceuticals in managing key functional areas and board directorships at Connect Biopharma, Elicio Therapeutics, and LAVA Therapeutics. “I look forward to having Karen on board as she bolsters Serina’s strategies and helps the company achieve great strides in delivering transformative therapies to the patients,” said Steve Ledger, CEO of Serina.

Ms. Wilson stated her interest in getting involved in Serina at such a time of this growth was eagerly welcomed. She said that she wants to work with the executive team and the other board of directors to continue supporting the company in its mission of positively changing patient’s lives. Also, Serina said that Steven Mintz resigned as a director of the company from its Board of Directors. Mr. Ledger accepted his responsibility and said that he had tried to contribute to the change of Serina’s status from a private limited to a public limited company so that the company has the best base for future development.